Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study

Yara Refaat Hassan¹,², Filipe Brogueira Rodrigues¹,², Paul Zeun³, Lauren M. Byrne¹, Carlos Estevez-Fraga³, Rosanna Tortelli³, Rachael I. Scahill¹, Edward J. Wild¹,³*, & Sarah J. Tabrizi¹,³*

Lumbar puncture (LP) has become increasingly common for people with Huntington’s disease (HD) both to administer intrathecal investigational medicinal products and to collect cerebrospinal fluid to develop biological markers to track disease stage and progression. We aimed to investigate the safety profile of LP in people with HD, building on a recently published work by increasing the sample size and more specifically, increasing the representation of the premanifest population and healthy controls. We conducted a multi-study cross-sectional analysis including eligible participants from the HDClarity (304 Huntington’s disease gene expansion carriers and 91 controls) and HD-YAS studies (54 premanifest and 48 controls), enrolled between February 2016 and September 2019. We investigated the odds of any adverse events, headaches, and back pain independently. Intergroup comparisons and adjusted event odds were derived using hierarchical logistic regressions. A total of 669 LP procedures involving 497 participants were included in this analysis. There were 184 (27.5%) LP procedures associated with one or more adverse events. The two most common adverse events were: post LP headache and back pain. Younger age and female gender were found to be associated with a higher risk of developing adverse events. There was no difference in the rate of adverse events between the disease subgroups after adjusting for covariates such as age and gender. Our results suggest that the LP is safe and tolerable in premanifest and manifest HD subjects, providing useful reassurance about the procedure to the HD community.

Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative disease resulting from CAG trinucleotide repeat expansion in the HTT gene located on the short arm of chromosome 4. The disease is characterized by a triad of movement disorder, cognitive impairment, and behavioural disturbances.

There has been an increase in research lumbar punctures (LP) performed in people with HD. This is led by the current search for objective and quantitative biomarkers that could define disease onset, track its progression, and serve as outcome measures in clinical trials of disease-modifying therapeutics; and by the utilization of the intrathecal route of drug administration in several clinical development programs, most remarkably of the antisense oligonucleotides (ASOs).

LP is a generally well-tolerated procedure, and experience from memory clinics and Parkinson’s disease shows that is a safe procedure, with relatively frequent mild and self-limiting adverse events and very rare severe or serious complications.

However, the literature is limited when it comes to HD, where several factors may impact safety and feasibility in this population such as the relatively young age of participants usually recruited in HD clinical trials compared to those with dementia, Parkinson’s disease, and Alzheimer’s disease; the characteristic brain atrophy associated

¹UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, 10-12 Russell Square House, London WC1B 5EH, UK. ²These authors contributed equally: Yara Refaat Hassan and Filipe Brogueira Rodrigues. ³These authors jointly supervised this work: Edward J. Wild and Sarah J. Tabrizi. *email: e.wild@ucl.ac.uk; s.tabrizi@ucl.ac.uk
with Huntington’s disease progression and its effect on the tolerance of post LP low-pressure syndrome; the variable degree of involuntary movement disorder that could pose some difficulties and challenges during the LP procedure; and also the neuropsychiatric manifestations that might affect their judgment, tolerability and their attitude toward the procedure.

A recent study by Rodrigues et al. addressed the first time the safety profile of LP in a cohort of patients with Huntington’s disease and controls who took part in the largest CSF collection initiative, HDClarity. They found that the adverse events rate in their cohort was similar to that reported in other neurological diseases or the general population and that age, gender, BMI, and disease burden score (DBS), as a surrogate of disease status, did not show association with the rate of post LP headache.

We adopted an individual patient data meta-analysis approach to build on this recently published work, by combining two cohorts to generate a substantially larger sample size (669 LP vs. 459 LP) and therefore higher statistical power; and also to increase the representation of premanifest HD, a population in which a higher risk of post-LP complications might be expected (given their young age); and finally to include substantially more controls, matched across the whole range.

This larger representation of subjects with HD in general, and of those at the premanifest stage in particular, are increasingly the focus of new therapeutic trials for HD, so we hoped that this approach would help to inform future clinical trials.

Methods

Study design. We conducted an individual patient data meta-analysis of two studies: HDClarity and HD-YAS.

The HDClarity study (NCT02855476) is an ongoing, international, multi-site, longitudinal CSF collection initiative aiming to recruit 1200 participants. The primary objective is to collect high-quality CSF samples for the evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The study protocol can be found at https://hdclarity.net.

The Huntington’s Disease Young Adult Study (HD-YAS) is a single centre cross-sectional study aimed at identifying the earliest signs of changes in brain structure and function caused by the HD mutation, including CSF biomarkers, in a cohort of 64 young adult premanifest gene carriers, selected to be relatively far from the onset, compared to 67 healthy controls. The study protocol can be found at https://www.ucl.ac.uk/ions/sites/ion/files/hd-yas_protocol_v6.0_sep18_signed.pdf.

Ethical considerations. The Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) standards were followed. For HDClarity, all participating sites sought appropriate ethical approval in accordance with each country’s specific legislation. HDClarity was approved by London—Camberwell St Giles Research Ethics Committee (16/LO/1878).

HD-YAS was approved by the Bloomsbury Research Ethics Committee (16/LO/1323). Participants had signed informed consent that is written and administered in compliance with the ICH-GCP requirement.

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Study participants. We grouped participants into three categories: healthy controls, premanifest HD, and manifest HD.

Controls were defined as participants who were either at risk of inheriting the expanded mutant gene but have tested negative in predictive genetic testing (HTT gene CAG < 36) or were family members or friends who were not at risk of inheriting the expanded mutation, and therefore, they had not undergone predictive genetic testing. HD gene expansion carriers (HDGEC) (HTT gene CAG ≥ 36) were grouped into either premanifest HD or manifest HD based on whether or not they had clinical diagnostic motor features of HD according to the Unified Huntington’s Disease Rating Scale (UHDRS) Diagnostic Confidence Level (DCL) (i.e., manifest HD had UHDRS DCL = 4, while premanifest had DCL < 4).

We excluded from the analyses participants who did not undergo a LP.

Study procedures. In HDClarity, LP procedures were performed at a sampling visit within 30 days of the screening visit. There was an optional repeat sampling visit 4 to 8 weeks after the initial visit. Some eligible participants were invited to participate in the study more than one time, at least 11 months after the previous screening visits. In HD-YAS, CSF collection was an optional study component and performed once only.

Both protocols mandated subjects to fast from midnight before the LP and the LP was performed by trained and experienced study site investigators. The HDClarity and HD-YAS protocols specified a 22G Whitacre (atraumatic) needle, and the method of CSF collection was via gravity dripping. The volume of the collected CSF was between 15 to 20 mL of CSF at each CSF sampling visit.

The number of lumbar puncture attempts that were permitted by the protocol was limited to 3 per visit. It was recommended to place the participants in the lateral decubitus position for CSF collection and to use the intervertebral space of L4/5 or L3/4 for CSF collection. According to the judgment of the site investigators, participants were advised to either lie flat for up to one hour after the lumbar puncture procedure or to mobilize immediately.

Upon discharge, participants were instructed by the study site staff to stay hydrated and take over-the-counter pain relief medication, and lie flat in the bed if they develop post LP syndrome. Participants were also instructed to avoid heavy lifting or strenuous exercise for 24 h post LP.
Study assessments. The motor, cognitive and functional status was assessed using the UHDRS99 from the core Enroll-HD battery, including the total motor score (TMS), total functional capacity (TFC), independence scale (IS), symbol-digit modality test (SDMT), and stroop word reading (SWR). For HDClarity these were performed at either the screening visit before sampling or an associated Enroll-HD visit (https://www.enroll-hd.org) within the 2 months prior to screening. For HD-YAS they were performed on the day before sampling. The composite Unified Huntington’s Disease Rating Scale (cUHDRS) was used as it is considered one of the most sensitive clinical measures for HD progression across the functional, motor, and cognitive domains8–10. We employed a calibrated iteration of the cUHDRS11,12.

\[
c_{UHDRS} = \frac{TFC - 8.8}{2.8} - \frac{TMS - 34.4}{17.4} + \frac{SDMT - 25.2}{12.4} + \frac{SWR - 58.0}{21.2} + 10
\]

The Disease burden score (DBS) was calculated for each HDGEC using the formula13:

\[
DBS = (CAG - 35.5) \times \text{age}
\]

Monitoring and recording adverse events in each study. In both studies, study site staff were mandated by the protocol to call the participants 24 to 72 h after the sampling visit to record any adverse events. Participants were also instructed to contact the study site to report any adverse events at any time point post-procedure.

For the purpose of our analysis, all adverse events were included. Primary analyses focused on the occurrence of post-LP adverse events, headaches, and back pain.

Data management. Included HDClarity sampling visits occurred from February 2016 to September 2019, while the HD-YAS visits occurred from August 2017 to March 2019. Only fully independently monitored visits with complete data which had undergone quality control were included: 60 out of 729 visits were excluded.

Statistical methods. We performed an individual patient data meta-analysis to investigate the occurrence of post-LP adverse events, headaches, and back pain. All analyses were performed using Stata/SE 15.1 (StataCorp, College Station) software. The significance (alpha) level was defined as 0.05.

General demographic characteristics, clinical assessments, and lumbar puncture characteristics at the first sampling research visit for each participant were described and compared according to the participant’s disease status (control, premanifest and manifest) for the two studies together, without accounting for the study provenance. Continuous variables were reported as mean and SD; counts as median, IQR, minimum and maximum; and categorical variables as absolute (n) and relative frequencies (%). To investigate group differences, linear regression analysis was performed for dependent continuous variables, and logistic regression analysis was performed for dependent categorical variables.

Our outcomes of interest were the occurrence of post-LP adverse events, post-LP headaches, and post-LP back pain. Each of these outcomes was investigated independently.

Building a multivariable meta-analysis model to evaluate the odds of adverse events in each group of interest was an iterative process. The approach described below was repeated for each outcome of interest, first for all three studied participant subgroups and then for HDGEC only.

First, we explored several univariable generalized logistic models. All models had the outcome odds as the dependent variable and group membership as the fixed effect. To account for the research study’s provenance (i.e., HDClarity or HD-YAS), we used a random intercept for the study. Given that a fraction of the participants from HDClarity (n = 170 [25.41%]) attended multiple visits, we decided to also include a random intercept for participants, nested into the study random effect to account for repeated measures. A negligible fraction (n = 2 [0.30%]) of participants provided data to both studies but we only included them once. We considered including a crossed random effect. Unfortunately, our data did not converge on models with crossed random effects or a nested participant random intercept. This was likely due to a lack of available information or/and variability across random effects. As such, we used a model with a random intercept for study only.

To ensure the internal validity of our final model structure we run several sensitivity analyses using less parsimonious models: a fixed effect logistic model only including the first sampling visit for each participant; a mixed-effect logistic model including the first sampling visit for each participant and a random intercept for study; bootstrapped mixed-effect logistic model including one random sampling visit per participant.

Secondly, we selected which variables to include in the multivariable model. Age and CAG repeat count have a strong influence on HD-related phenomena14–18. We also included other covariates based on prior knowledge of their possible association with the development of adverse events: gender3,4 and Body Mass Index (BMI)17,18 for post-LP headaches. Also, the number of lumbar puncture attempts was included in the final multivariable model for post-LP back pain. As such, we decided to include them as fixed effects when possible. We investigated the associations of the following variables (age, gender, BMI, ethnicity, HHT CAG size, DBS, cUHDRS, TMS, TFC, IS, SDMT, SWRT, number of LP attempts, position, and space used during LP procedure and volume of CSF collected during the LP) with the exposure (group membership) and outcome of interest (adverse events or post-LP headaches or post-LP back pain) by means of univariable analyses. Variables considered associated with both the exposure and outcome were included in the final model in a stepwise fashion, starting with the ones with a larger magnitude of effect and comparing sequential model performance based on the log-likelihood ratio test. Collinearity was evaluated with Spearman rank correlations and data sparseness with cross-tabulation of data.
The final cohort included 497 participants (139 control, 179 premanifest HD, 179 manifest HD) from the two studies (395 participants from HDClarity and 102 participants from HD-YAS) with a median age of 43 years (range 19–77). The demographic and disease characteristics of the participants and the characteristics of the LP procedures are presented in Table 1. Participants at the premanifest stage were significantly younger (mean age was 37 years in premanifest versus 53 in the manifest group, p < 0.001). The number of male and female participants was well balanced (female 50.9%); however, this was not the case among subgroups where female participants made up 54.75% of the premanifest subgroup and 42.46% of the manifest subgroup. 97.8% of all participants was well balanced (female 50.9%); however, this was not the case among subgroups where female participants made up 54.75% of the premanifest subgroup and 42.46% of the manifest subgroup. 97.8% of all participants was well balanced (female 50.9%); however, this was not the case among subgroups where female participants made up 54.75% of the premanifest subgroup and 42.46% of the manifest subgroup. 97.8% of all

### Table 1. Baseline demographics and disease characteristics and CSF sample methodology at first LP visit.

| Group               | All subjects | Healthy control | Premanifest | Manifest | Group membership P-value | HC vs PM P-value | PM vs M P-value |
|---------------------|--------------|-----------------|-------------|----------|--------------------------|------------------|-----------------|
| N                   | 497          | 139             | 179         | 179      |                          |                  |                 |
| Age (years)         | 43.94 (13.62)| 41.92 (14.20)   | 36.693 (10.81)| 52.76 (10.46)| <0.001                   | <0.001           | <0.001          |
| Female              | 253 (50.91%) | 79 (56.83%)     | 98 (54.75%) | 76 (42.46%) | 0.018                    | 0.710            | 0.020           |
| Caucasian           | 486 (97.79%) | 136 (97.84%)    | 174 (97.21%)| 176 (98.32%)| 0.775                    | 0.721            | 0.479           |
| BMI                 | 26.16 (5.02) | 27.31 (3.56)    | 25.68 (4.97)| 25.73 (4.47)| 0.006                    | 0.004            | 0.919           |
| CAG                 | 43.03 (2.53) | N/A             | 42.68 (2.26)| 43.39 (2.73)| N/A                      | N/A              | 0.009           |
| DBS                 | 324.48 (113.98)| N/A            | 252.66 (79.81)| 396.30 (96.49)| N/A                      | N/A              | <0.001          |
| cUHDRS              | 15.54 (3.97) | 18.05 (1.60)    | 17.65 (1.65)| 11.33 (3.56)| <0.001                   | 0.154            | <0.001          |
| UHDRS-TFC score     | 11.83 (2.41) | 12.97 (0.21)    | 12.86 (0.62)| 9.91 (3.16)  | <0.001                   | 0.613            | <0.001          |
| UHDRS-TMS           | 12.75 (19.54)| 0.83 (1.82)     | 1.99 (3.27) | 32.89 (20.45)| <0.001                   | 0.407            | <0.001          |
| UHDRS-IS            | 93.68 (12.78)| 99.96 (0.42)    | 99.55 (2.14)| 82.93 (16.40)| <0.001                   | 0.715            | <0.001          |
| SDMT                | 46.54 (17.29)| 56.12 (11.69)   | 55.31 (11.20)| 29.77 (13.23)| <0.001                   | 0.555            | <0.001          |
| SWRT                | 86.83 (26.86)| 103.27 (17.19)  | 98.42 (18.35)| 62.19 (22.20)| <0.001                   | 0.285            | <0.001          |
| Number of LP attempts| 1.01 (1.60) | 1.14 (0.39)     | 1.21 (0.49)| 1.28 (0.56)  | 0.051                    | 0.218            | 0.197           |
| Lateral decubitus   | 428 (86.12%) | 117 (84.17%)    | 159 (88.83%)| 152 (84.92%)| 0.419                    | 0.226            | 0.275           |
| LP site             |              |                 |             |           |                          |                  |                 |
| L3-L4               | 250 (50.40%) | 80 (57.55%)     | 86 (48.31%) | 84 (46.93%) | 0.196–0.871              | 0.129–0.831      | 0.870–0.738     |
| L4-L5               | 213 (42.94%) | 52 (37.41%)     | 80 (44.94%) | 81 (45.25%) | 0.196–0.871              | 0.129–0.831      | 0.870–0.738     |
| other               | 33 (6.65%)   | 7 (5.04%)       | 12 (6.74%)  | 14 (7.82%) | 0.196–0.871              | 0.129–0.831      | 0.870–0.738     |
| CSF volume          | 18.96 (3.55) | 19.57 (3.77)    | 19.21 (2.44)| 18.23 (4.15)| 0.002                    | 0.363            | 0.009           |
| CSF RBCs count      | 25.15 (171.92)| 9.66 (30.72)   | 16.21 (94.32)| 46.83 (271.04)| 0.114                    | 0.737            | 0.096           |

### Results

#### Study participants and visit distribution.

Data included were collected in the period between February 2016 and Sep 2019.

The final cohort included 497 participants (139 control, 179 premanifest HD, 179 manifest HD) from the two studies (395 participants from HDClarity and 102 participants from HD-YAS) with a median age of 43 years (range 19–77). The demographic and disease characteristics of the participants and the characteristics of the LP procedures are presented in Table 1. Participants at the premanifest stage were significantly younger (mean age was 37 years in premanifest versus 53 in the manifest group, p < 0.001). The number of male and female participants was well balanced (female 50.9%); however, this was not the case among subgroups where female participants made up 54.75% of the premanifest subgroup and 42.46% of the manifest subgroup. 97.8% of all participants were of Caucasian ethnicity. The mean BMI was 26.2, SD 5.02.

The total number of included LPs was 669 (104 LPs from the HD YAS and 565 LPs from the HDClarity). Within HDClarity, 395 LPs were done at the first sampling visit, 156 LPs were done at a second sampling visit and 14 LPs were done at a 3rd sampling visit.

Out of 669 LP procedures, 492 LP procedures were done in patients who were either premanifest (231 LP procedures) or manifest (261 LP procedures).

Overall, 342 participants had a single LP and 155 had 2 or more LPs.

The majority of the lumbar puncture procedures were done in the lateral decubitus position (86%) via the L3-L4 (50%) space. 550 LP procedures (82%) were successful on the first attempt. The mean CSF volume collected was 19 ml (SD 3.55). 28.7% of all the CSF samples had erythrocyte counts of more than 5 cells/μL. 18.7% contained more than 10 cells/μL.
Univariable analyses. Adverse event description. Overall, there were 184 (27.5%) LP visits where one or more adverse event was reported (Table 2). The two most common adverse events were: post LP headache and post LP back pain, accounting for 116 (17.3%) and 68 (10.2%) of all lumbar puncture visits, respectively.

Most headache events resolved spontaneously, with or without over-the-counter analgesics, and were classed as mild to moderate except in one case which was graded as severe. Epidural blood patch was required in only 1 case.

All back pain events were graded between mild and moderate and resolved without sequela, with or without simple analgesics.

Of all lumbar puncture visits, 2.54% were associated with other events not classified as headache or back pain, for example, puncture site swelling, bruising or hematoma at the site of the procedure, nausea or vomiting, and vasovagal syncope.

Among the HDGEC group, the percentage of LP with adverse events was 27.03%, while the percentage in the control group was 28.81%.

Table 2. Observed frequencies of adverse events at all included LP visits.

| Adverse events | All procedures | LP in Control | LP in Premanifest | LP in Manifest |
|----------------|----------------|---------------|-------------------|---------------|
| N = 497        | LP = 349       | LP = 148      | p-value           |
| Age            | 44 (14)        | 46 (13)       | 40 (13)           | < 0.001       |
| Female         | 253 (51%)      | 168 (48%)     | 85 (57%)          | 0.058         |
| Caucasian      | 486 (98%)      | 343 (98%)     | 143 (97%)         | 0.25          |
| BMI            | 26.16 (5.02)   | 26.26 (5.10)  | 25.91 (4.83)      | 0.47          |
| HD category    |                |               |                   |
| Control        | 139 (28%)      | 98 (28%)      | 41 (28%)          | < 0.001       |
| Premanifest    | 179 (36%)      | 109 (31%)     | 70 (47%)          | < 0.001       |
| Manifest       | 179 (36%)      | 142 (41%)     | 37 (25%)          | < 0.001       |
| DBS            | 324.48 (113.98)| 340.69 (113.27)| 286.34 (106.79) | < 0.001       |
| UHDRS-TFC score| 11.83 (2.41)   | 11.61 (2.61)  | 12.34 (1.71)      | 0.002         |
| UHDRS-IS       | 93.68 (12.78)  | 92.61 (13.83) | 96.22 (9.45)      | 0.004         |
| UHDRS-TMS      | 12.75 (19.54)  | 15.04 (21.24) | 7.37 (13.39)      | < 0.001       |
| SWRT           | 86.83 (26.86)  | 84.80 (27.81) | 91.57 (23.93)     | 0.010         |
| SDMT           | 46.54 (17.29)  | 44.67 (17.66) | 50.87 (15.60)     | < 0.001       |
| cUHDRS         | 15.54 (3.97)   | 15.14 (4.17)  | 16.47 (3.31)      | < 0.001       |
| Number of LP attempts | 1 (0) | 1 (0) | 1 (1) | 0.71 |
| LP site        |                |               |                   |
| L4/5           | 213 (43%)      | 152 (44%)     | 61 (41%)          | 0.45          |
| L3/4           | 250 (50%)      | 176 (50%)     | 74 (50%)          |               |
| other          | 33 (7%)        | 20 (6%)       | 13 (9%)           |               |
| Lateral decubitus| 428 (86%)  | 299 (86%)     | 129 (87%)         | 0.66          |
| CSF volume     | 19 (4)         | 19 (3)        | 19 (4)            | 0.90          |
| CSF RBCs count | 25 (172)       | 32 (204)      | 9 (31)            | 0.17          |

Table 3. Baseline demographics and CSF sample methodology in relation to the development of adverse events. Continuous variables are reported as mean (standard deviations). Categorical variables are reported as absolute and relative frequencies. BMI body mass index, CAG HTT CAG size, DBS Disease Burden Score, cUHDRS composite Unified Huntington’s Disease Rating Scale, TMS UHDRS Total Motor Score, TFC UHDRS Total Functional Capacity, IS UHDRS Independence Scale, SWR Stroop Word Reading test, SDMT Symbol Digits Modality Test, RBCs Red Blood Cells.
The unadjusted odds ratio of developing headache was significantly lower in the manifest subgroup compared to the controls (OR 0.50, 95% CI 0.28–0.89, \( p = 0.019 \)). However, since the control group was matched to the overall HDGEC population, the manifest subgroup was older than the control group on average (mean age was 52.76 in manifest versus 43.94 in healthy control). There was no difference in the odds ratio of developing post-LP back pain between the two groups (OR 0.91, 95% CI 0.45–1.87, \( p = 0.81 \)).

Age and gender were not found to be effect modifiers for any of the studied outcomes (adverse events, headache, and back pain) and the disease category.

Factors affecting the incidence of post-LP adverse events. The mean age for all participants who developed adverse events was lower (mean 40, SD 13) compared to those who did not develop adverse events (mean 46, SD 13, \( p < 0.001 \)). The OR for adverse events for each yearly increment in age was 0.96. This age difference was also significant in HDGEC.

The mean cUHDRS was higher in participants with adverse events (mean 16.47, SD 3.31) than in participants without adverse events (mean 15.14, SD 4.17, \( p < 0.001 \)). The mean BMI was similar (mean 26, SD 5) among those who developed any adverse events, headache, or back pain, and those who did not, with an odds ratio around 1 (OR = 0.99) and with a non-significant \( p \)-value (\( p = 0.54 \) for adverse events and headache, \( p = 0.69 \) for back pain).

The LP characteristics distribution was similar among participants who experienced and who did not experience adverse events.

Factors affecting the incidence of post-LP headaches. The manifest group of participants had the least number of headache events (22%) compared to the control and premanifest subgroups (30% and 48% respectively) (Table 5).

The participants who developed headaches post LP were younger compared to those who did not. (mean 41, SD 13 and mean 45, SD 14) (\( p = 0.007 \)). This age difference was also significant among the subgroup of gene expansion carriers (manifest and premanifest).

Females had more headache events post LP than males (59%); however, this difference was not significant (\( p = 0.078 \)), and the same was observed in the gene expansion carrier group of participants (57% of those who developed headaches were females, \( p = 0.14 \)).

There was no significant difference in the BMI of the participants with and without headache (mean BMI = 25.91 compared to 26.21, \( p = 0.61 \)).

Table 4. Univariable analysis of all adverse events, headache and back pain. BMI body mass index, CAG HTT CAG size, DBS Disease Burden Score, cUHDRS composite Unified Huntington’s Disease Rating Scale, Pre-M Premanifest HD, M Manifest, HDGEC Huntington’s disease gene expansion carrier, TMS UHDRS Total Motor Score, TFC UHDRS Total Functional Capacity, IS Independence Scale, SWR Stroop Word Reading test, SDMT Symbol Digits Modality Test, LD Lateral Decubitus, RBCs Red Blood Cells.
Factors affecting the incidence of post-LP back pain. The mean age for participants who developed back pain following LP was lower when compared to participants who did not have back pain post LP (mean 37, SD 12 and mean 45, SD 14, \( p < 0.001 \)) (Table 6).

The female percentage in the group who developed back pain after LP was also higher than those who did not develop back pain (55% compared to 50%) with a non-significant \( p \)-value (\( p = 0.48 \)).

The BMI mean was also not significantly different between the two groups (mean = 25.79 in the group who developed back pain compared to mean = 26.20 in the other group) (\( p = 0.56 \)).

Multivariable analysis. The results of the final multivariable analysis models showed that the adjusted odds ratio (OR) for developing adverse events in premanifest compared to control was 1.18 (95% CI 0.76–1.84), \( p \)-value 0.451.

The adjusted odds ratio for manifest compared to control was 0.87, 95% CI 0.53–1.42, \( p \)-value 0.578.

While for developing headaches, the adjusted odds ratio (OR) was 1.06 in premanifest versus control, (95% CI 0.65–1.73), \( p \)-value 0.82 and it was 0.55, 95% CI 0.31–0.98, \( p \)-value 0.44 in manifest compared to control.

The adjusted odds ratio (OR) for developing backache in premanifest versus control was 1.70 (95% CI 0.87–3.32), \( p \)-value 0.121.

The adjusted odds ratio for developing adverse events in manifest versus control was 1.69, and the 95% Conf. Interval [0.76–3.77], \( p \)-value 0.202 (Table 7), Fig. 1.

Discussion

Here we performed the largest investigation to date of LP procedure safety and feasibility in patients with Huntington’s disease, using a much larger sample size than prior reports, to improve the statistical power and including a larger number of premanifest participants towards whom new treatment trials will be directed, analysing data from 669 LP visits over more than 3 years. We have paid special attention to studying disease status (control, manifest or premanifest) as a potential factor that was not previously addressed in other studies.

The incidence of adverse events, post LP headache, and post LP back pain among our HDGEC population in this analysis is aligned with that reported in other studies in Huntington’s disease, or other populations such as Parkinson’s disease, Alzheimer’s Disease, and in a large study of patients attending memory clinics.
Adverse events were generally significantly higher in younger participants. The same is also true for post lumbar puncture headache and post lumbar puncture back pain. These results confirm what is previously known about older age as a preventive factor\(^{21,22}\).

In alignment with the above, the rate of post LP headache in HD-YAS participants, in whom a mean age of 29.16 years, was much higher (29.81%) than the rate of post LP headache among HDClarity participants (15.04%, who have a mean age of 49.38 years).

The impact of age on adverse events rate may also partially explain the results of disease status in this analysis. As the initial univariable analysis showed that the manifest subgroup of patients had fewer adverse events when compared to premanifest and control subgroups, this was not the case after adjusting for covariates like age and gender.

However, the final multivariable analysis model confirmed that the disease status did not influence the rate of developing adverse events.

### Table 6. Baseline demographics and CSF sample methodology in relation to the development of back pain post LP. Continuous variables are reported as mean (standard deviations). Categorical variables are reported as absolute and relative frequencies. SD Standard deviation, BMI body mass index, CAG HTT CAG size, DBS Disease Burden Score, cUHDRS composite Unified Huntington’s Disease Rating Scale, TMS UHDRS Total Motor Score, TFC UHDRS Total Functional Capacity, IS UHDRS Independence Scale, SWR Stroop Word Reading test, SDMT Symbol Digits Modality Test, RBCs Red Blood Cells.

| Back pain          | Total (N = 497) | Procedures without adverse events (100%) (N = 441) | Procedures with Adverse events (100%) (N = 56) | p-value |
|--------------------|----------------|-----------------------------------------------|-----------------------------------------------|---------|
| Age                | 44 (14)        | 45 (14)                                       | 37 (12)                                       | <0.001  |
| Female             | 253 (51%)      | 222 (50%)                                     | 31 (55%)                                      | 0.48    |
| Caucasian          | 486 (98%)      | 433 (98%)                                     | 53 (95%)                                      | 0.090   |
| BMI                | 26.18 (5.02)   | 26.20 (5.07)                                  | 25.79 (4.64)                                  | 0.56    |
| **HD category**    |                |                                               |                                               |         |
| Premanifest        | 139 (28%)      | 127 (29%)                                     | 12 (21%)                                      | 0.033   |
| Manifest           | 179 (36%)      | 150 (34%)                                     | 29 (52%)                                      |         |
| Control            | 182 (36%)      | 167 (37%)                                     | 15 (27%)                                      |         |
| DBS                | 324.48 (113.98)| 331.16 (112.78)                               | 278.45 (112.24)                               | 0.003   |
| UHDRS-TFC score    | 11.83 (2.41)   | 11.78 (2.48)                                  | 12.25 (1.67)                                  | 0.17    |
| UHDRS-IS           | 93.68 (12.78)  | 93.29 (13.29)                                 | 96.79 (7.10)                                  | 0.054   |
| UHDRS-TMS          | 12.75 (19.54)  | 13.52 (20.25)                                 | 6.73 (11.00)                                  | 0.014   |
| SWRT               | 86.83 (26.86)  | 86.52 (27.34)                                 | 89.21 (22.81)                                 | 0.48    |
| SDMT               | 46.54 (17.29)  | 46.08 (17.64)                                 | 50.11 (13.89)                                 | 0.01    |
| cUHDRS             | 15.54 (3.97)   | 15.44 (4.08)                                  | 16.30 (2.97)                                  | 0.13    |
| Number of LP attempts | 1 (0)       | 1 (0)                                         | 1 (1)                                         | 0.81    |
| **LP Site**        |                |                                               |                                               |         |
| L4/5               | 213 (43%)      | 191 (43%)                                     | 22 (39%)                                      | 0.17    |
| L3/4               | 250 (50%)      | 223 (51%)                                     | 27 (48%)                                      |         |
| Other              | 33 (7%)        | 26 (6%)                                       | 7 (13%)                                       |         |
| Lateral decubitus  | L3/4           | 378 (86%)                                     | 50 (89%)                                      | 0.47    |
| CSF volume         | Other          | 19 (3)                                        | 19 (5)                                        | 0.31    |
| CSF RBCs count     | 25 (172)       | 27 (182)                                      | 7 (15)                                        | 0.40    |

### Table 7. Results of multivariable analysis of models in premanifest compared to control participants and in manifest compared to control participants. HDGEC HD gene expansion carrier, OR Odd ratio.

| Multivariable analysis | Adverse events OR 95% CI | Headache OR 95% CI | Back pain OR 95% CI |
|------------------------|---------------------------|--------------------|---------------------|
| Premanifest vs control | 1.18 [0.76–1.84]          | 1.06 [0.65–1.73]   | 1.70 [0.87–3.32]    |
| OR 95% CI               |                           |                    |                     |
| Manifest vs control    | 0.87 [0.53–1.42]          | 0.55 [0.31–0.98]   | 1.69 [0.76–3.77]    |
| OR 95% CI               |                           |                    |                     |
| HDGEC vs control       | 1.046 [0.70–1.56]         | 0.832 [0.54–1.30]  | 1.70 [0.91–3.20]    |
| OR 95% CI               |                           |                    |                     |
The reduced incidence of post LP headache in older age groups was hypothetically linked in several studies to brain atrophy\textsuperscript{23–25}; thus, studying the association between brain volume and the development of post LP headache in patients with Huntington’s disease, independent of age, would be an interesting point to be tested in future studies.

Consistent with other studies\textsuperscript{3,26}, female participants were found to be at higher risk of developing any adverse events, headaches, and back pain than male participants. This was also true in the sub-analysis of CAG gene expansion carrier participants. There is no clear explanation for the gender effect.

In our analysis, we had a wide range of BMI values ranging from 16 to 55 kg/m\textsuperscript{2} as neither of the included studies in this analysis had any specific inclusion criteria related to participants’ weight or BMI. BMI was not found to affect the incidence of post-LP adverse events. This is consistent with previous studies\textsuperscript{3}.

Despite the relatively high volume of CSF collected (20 ml) during lumbar puncture procedures included in our analysis, this did not result in a rise in the rate of adverse events compared to other studies with lower CSF volume collected and provides reassurance that collecting such volumes is safe and well-tolerated.

The position of the participant during the lumbar puncture procedure did not appear to have any significant impact on the incidence of adverse events. Hence, we would recommend that future designs of clinical trials allow the site investigators to choose the appropriate position for their participants based on their experience and preference unless either of the positions is preferred for a different reason e.g., an upright sitting position to measure the CSF opening pressure.

A major strength of this work is that it pools participants from two studies to improve statistical power and clinical diversity; however, this also comes at the cost of potential variability between studies. The mean age for those who came from HD-YAS was much younger than those from HDClarity, also, while both studies had premanifest and control subjects, the manifest group only came from the HDClarity study. To overcome this, the multivariable model was built accounting for study provenance.

HDClarity is a large multisite study and data included in this analysis came from different sites globally which subsequently could be a cause of variation in reporting and monitoring adverse events.

Needle gauge is well-established to be significantly associated with the rate of development of post LP Headache\textsuperscript{2,3,25}. In our study, this factor could not be analysed in relation to the development of adverse events as only one size (22G) was used in all participants; however, the reported rate of post LP headache in our study, in which 22G needle size was used, is generally aligned with the reported rate of post LP headache in studies where needle size 24G was used such as in the Tomierno\textsuperscript{sen ASO development program}\textsuperscript{19,27}.

Given that many potential factors could possibly affect the incidence rate of post LP adverse events, a larger sample size would be more appropriate and will give better statistical power.

It is important to note that our analysis did not take into account the duration of events of interest and potential right-censoring related to the limited observation period after the visits.

---

**Figure 1.** Odds ratio and 95\%CI of adverse events in premanifest and manifest participants when compared to control participants. OR odds ratio.
Another limitation in our analysis is the inclusion of all reported headache events. There were three cases of tension headaches and four cases of migraine headaches that were described by the study site investigator as unrelated to LP procedure, there were 17 events of non-postural mild headache related to the LP but not classified as a typical low-pressure syndrome.

An important point to reflect on is that our cohort in this analysis came from subjects selected for participation in observational research; their characteristics may not be representative of people with HD in general, or of participants in interventional therapeutic trials.

In summary, our results suggest that the lumbar puncture procedure is safe and tolerable in premanifest and manifest Huntington’s disease subjects. This information is useful to be communicated to the Huntington’s disease community to encourage participation in clinical trials and to reduce any anxiety relating to the procedure.

Data availability
All data generated during this study are not publicly available, however, they are available from the corresponding author on reasonable request and with permission of CHDI Foundation, Inc.

Received: 22 July 2022; Accepted: 6 October 2022

Published online: 01 November 2022

References
1. MacDonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983 (1993).
2. Engleberghs, S. et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer’s Dement. Diagn. Assess. Dis. Monit. 8, 111–126 (2017).
3. Prakash, N. et al. Feasibility and safety of lumbar puncture in the Parkinson’s disease research participants: Parkinson’s progression marker initiative (PPMI). Park. Relat. Disord. 62, 201–209 (2019).
4. Duits, F. H. et al. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer’s Dement. 12, 154–163 (2016).
5. Rodrigues, F. B. et al. Safety and feasibility of research lumbar puncture in Huntington’s disease: The HDClarity cohort and biore- source. medRxiv https://doi.org/10.1101/2021.07.30.21261340 (2021).
6. Schall, R. I. et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease young adult study (HD-YAS): A cross-sectional analysis. Lancet Neurol. 19, 502–512 (2020).
7. Landwehrmeyer, G. B. et al. Data analytics from enroll-HD, a global clinical research platform for Huntington’s disease. Mov. Disord. Clin. Pract. 4, 212–224 (2017).
8. Trundell, D. et al. Defining Clinically Meaningful Change on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS). Neurology 92, P1.8–043 (2019).
9. Buzelius, E. et al. Huntington’s disease in the United States: Variation by demographic and socioeconomic factors. Mov. Disord. 34, 858–865 (2019).
10. Gooding, M. et al. Enrichment strategy in early-to-moderate manifest Huntington disease based on CAG/Ag product (CAP) > 400 threshold. Neurotherapeutics 15, 1186 (2018).
11. Trundell, D. et al. F23 Validity, reliability, ability to detect change and meaningful within-patient change of the CUDHRS. A48.1-A48. https://doi.org/10.1136/jnnp-2018-chdnr.127(2018).
12. Schobel, S. A. et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 89, 2495 (2017).
13. Penney, J. B., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann. Neurol. 41, 689–692 (1997).
14. Langbehn, D. R. et al. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153, 403–408 (2010).
15. Ghazaleh, N. et al. Ranking the predictive power of clinical and biological features associated with disease progression in Huntington’s disease. Front. Neurol. 0, 814 (2021).
16. Zhang, Y. et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156, 751 (2011).
17. van Oosterhout, W. P. J. et al. Postdural puncture headache in migraineurs and nonheadache subjects: A prospective study. Neurology 80, 941–948 (2013).
18. Arevalo-Rodriguez, I. et al. Needle gauge and tip designs for preventing post-dural puncture headache (PDPH). Cochrane Database Syst. Rev. (2017).
19. Fabrizz, S. et al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).
20. Alcolae, D. et al. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer’s disease: A multicenter study in Spain. J. Alzheimer’s Dis. 39, 719–726 (2014).
21. Evans, R. W., Armon, C., Frohman, E. M. & Goodin, D. S. Assessment: Prevention of post–lumbar puncture headaches. Neurology 55, 909–914 (2000).
22. Leibold, R. A., Yealy, D. M., Coppola, M. & Cantees, K. K. Post-dural-puncture headache: Characteristics, management, and prevention. Ann. Emerg. Med. 22, 1863–1870 (1993).
23. Hindley, N. J. et al. High acceptability and low morbidity of diagnostic lumbar puncture in elderly subjects of mixed cognitive status. Acta Neurol. Scand. 91, 405–411 (1995).
24. Mayer, D. C. & Spilman, F. J. Postdural Puncture Headache. Decis. Mak. Anesthesiol. https://doi.org/10.1016/B978-0-323-03938-3.00213-X (2022).
25. Monserrate, A. E. et al. Factors associated with the onset and persistence of post-lumbar puncture headache. JAMA Neurol. 72, 332–332 (2015).
26. Moulder, K. L. et al. factors influencing successful lumbar puncture in alzheimer research. Alzheimer Dis. Assoc. Disord. 31, 287–294 (2017).
27. Roche & Genentech. Preliminary results from GENERATION HD1, a Phase III trial of tominersen in individuals with manifest HD – CHDI-2021-presentation-schobel-an-update-from-the-tominersen-global-clinical-development-programme.pdf. https://medicallygene.com/global/en/unrestricted/neuroscience/CHDI-2021/chdi-2021-presentation-schobel-an-update-from-the-tomin. html (2021).
Acknowledgements
This publication used samples and data from the HDClarity sample collection, which would not be possible without the generous contribution of samples and data from the research participants—we thank them and their families. The HDClarity study is led by Prof. Edward Wild, sponsored by University College London, and funded by CHDI Foundation, Inc., a non-profit biomedical research organization exclusively dedicated to developing therapeutics that will substantially improve the lives of HD-affected individuals. The Medical Research Council UK (MR/M008592/1) funded the HD-CSF study that also provides samples to the HDClarity sample collection. We acknowledge the effort made by HD-YAS and HDClarity studies investigators. We greatly appreciate the contribution made by all the participants in these two studies, giving their time and efforts and donating their blood samples and CSF samples for the purpose of scientific research and clinical trials developments, and also, we thank their families and friends who supported them in their participation.

Author contributions
E.J.W. and S.J.T. conceived the idea for the research project and contributed to the study design. Y.H. and F.B.R. contributed to the study design and execution, statistical analysis design and execution, and writing of the first draft. F.B.R., P.Z., L.M.B., C.E.F., R.T., and R.I.S. contributed to the original data collection. All authors made substantial contributions, including critical revision of the manuscript and all authors have given approval to the final version of the manuscript.

Funding
The HDClarity study is sponsored by UCL and funded by CHDI Foundation, Inc., a not-for-profit organization dedicated to developing treatments for Huntington's disease. The HD-YAS study is funded by the UK Wellcome Trust (Collaborative Grant 200181/Z/15/Z) and CHDI Foundation and sponsored by UCL. EJW was supported by Medical Research Council UK (MR/M008592/1) and CHDI Foundation. CE-F received support from a Wellcome Trust Collaborative Award (200181/Z/15/Z). FBR is a Medpace UK Ltd employee and was a University College London employee during the conduct of this study. FBR salary at UCL was supported by CHDI Foundation. FBR received consultancy fees from GLG, Roche, Evigrade and is now an employee of Medpace Ltd. RT is a full employee of F.Hoffmann La Roche Ltd and was a University College London employee during her contribution to this study. EJW reports consultancy / advisory board memberships with Annexon, Remix Therapeutics, Hoffman La Roche Ltd, Ionis Pharmaceuticals, PTC Therapeutics, Takeda, Teitur Trophics, Triplet Therapeutics, and Vico Therapeutics. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly-owned subsidiary of University College London.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-21934-6.

Correspondence and requests for materials should be addressed to E.J.W. or S.J.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022